|
|
Advax |
|
Vaxjo ID |
119 |
|
Vaccine Adjuvant Name |
Advax |
|
Adjuvant VO ID |
VO_0005207
|
|
Description |
carbohydrate derived from delta inulin with complement receptor found within dendritic cells; induces Th1/Th2 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Adelaid, Australia |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
polysaccharide semi-crystalline particles of delta inulin |
|
Storage |
Store refrigerated at 2-8C or at room temperature. Do not freeze |
|
Preparation |
inulin is formulated into delta-inulin --> microparticles of 1–5 μm size ; based on the plant derived fructan inulin |
|
Function |
Type: TLR agonist vaccine adjuvant. Induces Th1/Th2 mixed immune profile. Dendritic cell maturation |
| Related Vaccine(s) |
|
| References |
(Petrovsky, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=37]
Gordon et al., 2014: Gordon D, Kelley P, Heinzel S, Cooper P, Petrovsky N. Immunogenicity and safety of Advaxâ„¢, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine. 2014; 32(48); 6469-6477. [PubMed: 25267153].
Wanandy et al., 2019: Wanandy T, Honda-Okubo Y, Davies NW, Rose HE, Heddle RJ, Brown SGA, Woodman RJ, Petrovsky N, Wiese MD. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. Journal of pharmaceutical and biomedical analysis. 2019; 172; 1-8. [PubMed: 31009889].
|
|
